FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis

The FDA on Tuesday approved UCB’s zilucoplan, now to be marketed under the brand name Zilbrysq, for the treatment of generalized myasthenia gravis in patients who are positive for antibodies against the acetylcholine receptor.